Patent Fees Increasing, Driven By Fewer Filings, Jump In PTAB Workload
Executive Summary
US Patent and Trademark Office proposes 5% across the board patent fee adjustment plus targeted fee hikes; Patent Trial and Appeal Board costs have risen following Supreme Court's SAS Institute decision.
You may also be interested in...
Inter Partes Patent Challenges Are Constitutional, US Supreme Court Rules
But Patent Trial and Appeals Board must issue final written decision on all claims raised by challenger – not just some of them, court says; rulings in two closely watched cases mean that IPR proceedings can continue unabated, but generic drug and biosimilar sponsors may need to rethink how they go about challenging innovator patent claims.
IPR Battles Could Become Easier For BioPharma Patent Owners
En banc Federal Circuit says patent owners do not have to prove patentability of amended claims in inter partes review proceedings; judges issue five opinions in fractured decision.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.